论文部分内容阅读
目的观察疏风解毒胶囊治疗支气管扩张合症并肺部感染的临床疗效及安全性。方法将100例支气管扩张合并肺部感染的患者按入院顺序分成治疗组和对照组。对照组予以乳酸左氧氟沙星氯化钠注射液,每次0.6 g,静脉滴注,每日1次;治疗组在对照组基础上同时口服疏风解毒胶囊,每次4粒,口服,每日3次。2组患者同时予排痰、促进痰液排出、退热等治疗,连续10天。观察2组治疗第3、7天感染指标变化情况,及治疗第10天临床效果、不良反应发生情况。结果治疗第3天,治疗组患者血白细胞、C反应蛋白水平低于对照组(P<0.05,P<0.01)。治疗第7天,治疗组C反应蛋白水平低于对照组,2组血白细胞比较差异无统计学意义(P>0.05)。治疗第10天,治疗组总有效率高于对照组,差异有统计学意义(P<0.05)。2组均未出现明显的药物不良反应。结论疏风解毒胶囊联合抗生素治疗支气管扩张合并肺部感染,能够加快感染控制,促进患者恢复。
Objective To observe the clinical efficacy and safety of Shufeng Jiedu Capsule in the treatment of bronchiectasis and pulmonary infection. Methods One hundred patients with bronchiectasis and pulmonary infection were divided into treatment group and control group according to admission order. The control group was given levofloxacin lactate lactate injection, each 0.6 g, intravenous infusion, once daily; the treatment group in the control group based on oral Shufeng Jiedu capsule, 4 capsules each time, orally, 3 times a day . Patients in both groups were also excreted to promote sputum discharge, fever and other treatment for 10 days. The changes of infection indexes on the 3rd and 7th days in the two groups were observed, and the clinical effects and adverse reactions on the 10th day of treatment were observed. Results On the third day after treatment, the level of leukocyte and C-reactive protein in the treatment group was lower than that in the control group (P <0.05, P <0.01). On the 7th day after treatment, the level of C-reactive protein in the treatment group was lower than that in the control group. There was no significant difference in the two groups of white blood cells (P> 0.05). On the 10th day of treatment, the total effective rate of the treatment group was higher than that of the control group, the difference was statistically significant (P <0.05). No obvious adverse drug reactions occurred in both groups. Conclusion Shufeng Jiedu capsule combined with antibiotics in the treatment of bronchiectasis with pulmonary infection can speed up infection control and promote patient recovery.